Product Images Gemcitabine

This is a comparison of progression-free survival between Gemcitabine/Carboplatin and Carboplatin alone in a study with 178 participants for each treatment. The data includes the median progression-free survival and a graph showing the progression-free survival in months.*

This text provides a comparison of the median time to documented disease progression between two treatment groups - Paclitaxel alone and Gemcitabine/Paclitaxel combination. The data shows that the median time to documented disease progression for Gemcitabine/Paclitaxel is 5.2 months, while for Paclitaxel alone it is 2.9 months. The p-value from the log-rank test is reported to be less than 0.0001, suggesting a statistically significant difference between the two treatment groups. The findings are based on a sample size of 262 for Paclitaxel and 267 for Gemcitabine/Paclitaxel. Time to documented disease progression in months is graphed over a span of 24 months.*

This text provides information on the survival probability and median survival time for patients treated with Gem/Cis (combination of Gemcitabine and Cisplatin) compared to Cisplatin alone. The results show that Gem/Cis had a median survival time of 9.0 months with a 39% survival rate, while Cisplatin alone had a median survival time of 7.6 months with a 28% survival rate. The test statistics (Logrank and Wilcoxon) suggest a statistically significant difference between the two treatment groups. Additionally, the data includes the number of patients in each treatment group (N=260 for Gem/Cis and N=262 for Cisplatin) and the 1-year survival rate.*

This is a list of numerical values, symbols, and a medication name related to a chart or graph possibly showing survival time in months. The values range from 0.0 to 1.0 and there are some numeric values followed by abbreviation of medications "Gemcitabine" and "5-FU". There are also some singular numbers and symbols like 2, 5, @, <, 8, ki, £, [, 1.0, 0.9, and 0.8. This information seems to be a mix of data points and labels for a medical or statistical analysis, possibly related to cancer treatment.*

This text appears to be a medication label for Gemcitabine injection, containing 195 mg of Gemcitabine hydrochloride per vial. It should be diluted before use and administered intravenously. Gemcitabine is a potentially cytotoxic drug, so precautions should be taken during handling. The product is distributed by Hospira, Inc. It is advisable to store the medication at 2 to 8°C and discard any unused portion. For dosing and administration details, refer to the package insert.*

This is a medication description for Gemcitabine Injection, which is a potentially cytotoxic drug used intravenously. Each vial contains 2g of gemcitabine. It must be diluted before use and stored at 2 to 8°C. The medication is distributed by Hospira, Inc. under the brand novaplus. Care should be taken to prevent inhaling particles and skin exposure to the drug due to its cytotoxic nature.*

This text contains information about a medication called Gemcitabine Injection. It is a cytotoxic agent used for intravenous administration. Each vial contains 200 mg of gemcitabine and must be diluted before use. Care should be taken to prevent inhaling particles or skin exposure. The medication is distributed by Hospira, Inc., and should be stored at 2 to 8°C. Please refer to the package insert for dosing and administration instructions.*